Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) After Enouraging Durability Data Appears in NEJM
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $205.00 price target on Moderna (NASDAQ: MRNA) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
